Monopar Therapeutics announced the rolling submission of a New Drug Application for ALXN1840, its first-in-class albumin tripartite complex activator, to treat Wilson disease. The FDA has authorized rolling submissions, with Monopar having already provided the first completed sections of the NDA. If approved, ALXN1840 could become the first therapy with a novel mechanism of action for Wilson disease in decades. The company highlighted regulatory designations, including Fast Track, Orphan Drug, and Rare Pediatric Disease status, which may support expedited review and pediatric incentives. Monopar emphasized the potential to provide a copper-sequestering treatment for a lifelong, serious condition and noted ongoing Phase 2/3 data supporting the asset’s late-stage profile. These updates coincide with coverage from multiple outlets detailing the NDA filing and the company’s ongoing efforts to bring ALXN1840 to patients.